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Abstract: Sorafenib is a relatively new cytostatic drug approved for the treatment of renal 
cell and hepatocellular carcinoma. In this report we describe the synthesis of sorafenib 
derivatives 4a–e which differ from sorafenib in their amide part. A 4-step synthetic pathway 
includes preparation of 4-chloropyridine-2-carbonyl chloride hydrochloride (1), 4-chloro-
pyridine-2-carboxamides 2a–e, 4-(4-aminophenoxy)-pyridine-2-carboxamides 3a–e and the 
target compounds 4-4-4-chloro-3-(trifluoromethyl)phenylcarbamoylamino-phenoxy-
pyridine-2-carboxamides 4a–e. All compounds were fully chemically characterized and 
evaluated for their cytostatic activity against a panel of carcinoma, lymphoma and leukemia 
tumour cell lines. In addition, their antimetabolic potential was investigated as well. The most 
prominent antiproliferative activity was obtained for compounds 4a–e (IC50 = 14.3 μmol·L−1). 
Their potency was comparable to the potency of sorafenib, or even better. The compounds 
inhibited DNA, RNA and protein synthesis to a similar extent and did not discriminate 
between tumour cell lines and primary fibroblasts in terms of their anti-proliferative activity. 
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1. Introduction 
Sorafenib, 4-4-4-chloro-3-(trifluoromethyl)phenylcarbamoylaminophenoxy-N-methylpyridine- 
2-carboxamide, is an oral multikinase inhibitor that inhibits cell surface tyrosine kinase receptors  
(e.g., vascular endothelial growth factor receptors and platelet-derived growth factor receptor-beta) and 
downstream intracellular serine/threonine kinases (e.g., Raf-1, wild-type B-Raf and mutant B-Raf); 
these kinases are involved in tumour cell proliferation and tumour angiogenesis 1–3. Sorafenib is 
approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma 4,5. 
Clinical trials to use sorafenib for non-responsive thyroid cancer and glioblastoma are in progress as 
well. However, both median survival and time to progression in sorafenib therapy showed only a  
3-month improvement in patients who received sorafenib compared to placebo 6,7. These facts point 
to sorafenib as an interesting lead compound for further derivatization in order to find a more effective 
drug. The present study is focused on the synthesis of new sorafenib derivatives bearing the same 
diarylurea moiety as sorafenib and differing from the parent drug in the amide part. The newly 
prepared compounds are more lipophilic in an attempt to increase uptake and/or accumulation of the 
drug in tissues 8. Here we report their synthesis and in vitro evaluation of their cytostatic activity 
against several carcinoma cell lines. 
2. Results and Discussion  
2.1. Chemistry 
A four step synthesis of sorafenib amide analogues 4a–e is described. Scheme 1 outlines the general 
preparative route. The starting material, picolinic acid, was first converted to the acid chloride using 
thionyl chloride 9. Under the reaction conditions employed (72 °C, 16 h, nitrogen atmosphere), 
chlorination of the pyridine ring at the para-position occurred as well and the final product was  
4-chloropyridine-2-carbonyl chloride hydrochloride (1). Amidation of the acid chloride 1 with five 
different amines (cyclopentylamine, cyclohexylamine, cyclohexylmethylamine, benzylamine and 
phenylethylamine) gave amides 2a–e. The amidation step was performed at room temperature in the 
presence of triethylamine as HCl acceptor. The selected amines were chosen on the basis of their 
lipophilicity and limited number of possible conformations, providing more lipohilic and rigid final 
compounds 4. The reactions of acid chloride 1 with the title amines gave the amides in good yields. 
Amide 2c was also prepared from picolinic acid methyl ester (methyl 4-chloropyridine-2-carboxylate) 
and cyclohexylmethylamine. However, analogous reactions with cyclopentylamine and cyclohexyl-
amine afforded the corresponding amides in poor yields. 
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Scheme 1. Synthesis of sorafenib derivatives 4a–e. 
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Reagents and conditions: (i) SOCl2, DMF, N2 atmosphere, 72 C, 16 h; (ii) amine, TEA, toluene, rt, 
0.5 h; (iii); 4-aminophenol, t-BuOK, DMF, K2CO3, DMF, 10 min, 173 C, microwaves;  
(iv) 4-chloro-3-(fluoromethyl)phenyl isocyanate, CH2Cl2, N2 atmosphere, rt, 16 h. 
In the next reaction step products 2a–e were coupled with 4-aminophenol to give the ethers 3a–e. 
The ether side chain was introduced using potassium tert-butoxide in the presence of potassium 
carbonate (2 h, 80 C). Under basic conditions employed, the alkoxide derived from 4-aminophenol 
was a stronger nucleophile than the amino group, therefore the main product was the ether, not the 
secondary amine. The reaction time was shortened to 10 min when the ether formation reactions were 
run in a microwave reactor (P = 150 W, t = 173 °C). Ethers 3a–e readily reacted with isocyanate to 
give the final products 4a–e. Urea bond formation was performed at room temperature, in nitrogen 
atmosphere, using a slight excess of 4-chloro-3-(fluoromethyl)phenyl isocyanate. 
All intermediates and final amides 4a–e were isolated and fully characterized by elemental analysis 
and usual spectroscopic methods (IR, 1H-, 13C-NMR and MS). The spectral data are consistent with the 
proposed structures (Table 1). 
Table 1. 1H and 13C-NMR spectra of compounds 2a–e, 3a–e, and 4a–e. 
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Compd. R 1H and 13C-NMR spectra/δ ppm, J/Hz 
2a 2´
6´ 5´
4´
3´
 
8.62 (d, 1H, 3, J = 5.4), 8.58 (d, 1H, 1', J = 7.6), 8.02 (d, 1H, 6, J = 1.8), 7.75 (dd, 
1H, 4, J = 2.1, J = 3.2), 4.31–4.19 (m, 1H, 2'), 1.94–1.53 (m, 8H, 3'–6') 
161.26 (1), 151.02 (2), 149.02 (3), 143.61 (5), 125.36 (6), 120.98 (4), 49.82 (2'), 
31.12 (3', 6'), 22.62 (4', 5') 
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Table 1. Cont. 
Compd. R 1H and 13C-NMR spectra/δ ppm, J/Hz 
2b 
2´
7´
6´
5´
4´
3´
 
8.61 (d, 1H, 3, J = 5.2), 8.48 (d, 1H, 1', J = 8.1), 8.01 (d, 1H, 6, J = 1.9), 7.74 (dd, 
1H, 4, J = 1.9, J = 3.2), 3.80–3.74 (m, 1H, 2'), 1.79–1.16 (m, 10H, 3'–7') 
161.54 (1), 151.90 (2), 149.91 (3), 144.53 (5), 126.28 (6), 121.90 (4), 48.13 (2'), 
32.03 (3', 7'), 25.03 (5'), 24.73 (4', 6') 
2c 
2´
3´
8´
7´
6´
5´
4´
 
8.82 (t, 1H, 1', J = 8.8), 8.62 (d, 1H, 3, J = 8.6), 8.02 (d, 1H, 6, J = 1.8), 7.76 (dd, 
1H, 4, J = 2.1, J = 3.1), 3.16 (t, 2H, 2', J = 6.6), 1.68–0.97 (m, 11H, 3'–8') 
163.08 (1), 152.37 (2), 150.46 (3), 145.00 (5), 126.76 (6), 122.39 (4), 45.52 (2'), 
30.86 (4', 8'), 26.50 (6'), 25.81 (5', 7') 
2d 
2´
3´
8´
7´
6´
5´
4´
 
9.40 (t, 1H, 1', J = 6.2), 8.62 (d, 1H, 3, J = 5.5), 8.01 (d, 1H, 6, J = 2.0), 7.77 (dd, 
1H, 4, J = 2.1, J = 3.3), 7.33–7.21 (m, 5H, arom. 4'–8'), 4.50 (d, 2H, 2', J = 6.1) 
163.26 (1), 152.23 (2), 150.57 (3), 145.04 (5), 139.76 (3'), 128.72 (4', 8'), 127.83 (5', 7'), 
126.94 (6'), 125.36 (6), 120.98 (4), 42.98 (2') 
2e 
2´
3´
4´
9´
8´
7´
6´
5´
 
8.88 (t, 1H, 1', J = 5.6), 8.61 (d, 1H, 3, J = 5.0), 8.01 (d, 1H, 6, J = 1.8), 7.73 (dd, 
1H, 4, J = 2.1, J = 3.2), 3.55–3.52 (q, 2H, 2', J = 7.0), 2.86 (t, 2H, 3', J = 7.5) 
162.50 (1), 151.73 (2), 149.98 (3), 144.52 (5), 139.24 (4'), 128.54 (5', 9'), 128.31 (6', 8'), 
126.33 (6), 126.08 (7'), 121.86 (4), 40.44 (2'), 34.97 (3') 
3a 2´
6´ 5´
4´
3´
 
8.46 (d, 1H, 3, J = 2.5), 8.44 (d, 1H, 1', J = 8.5), 7.34 (d, 1H, 6, J = 2.4), 7.08 (dd, 
1H, 4, J = 2.6, J = 2.9), 6.85 (d, 2H, 8, 12, J = 8.9), 6.66 (d, 2H, 9, 11, J = 8.9), 5.16 
(s, 2H, 13), 4.22–4.15 (m, 1H, 2'), 1.99–1.53 (m, 8H, 3'–6') 
167.30 (5), 163.31 (1), 152.74 (2), 150.51 (3), 147.32 (7), 143.37 (10), 121.99 (8, 12), 
115.36 (9, 11), 114.23 (6), 108.86 (4), 51.04 (2'), 32.56 (3', 6'), 23.95 (4', 5') 
3b 
2´
7´
6´
5´
4´
3´
 
8.45 (d, 1H, 3, J = 5.7), 8.37 (d, 1H, 1', J = 8.5), 7.34 (d, 1H, 6, J = 2.4), 7.08 (dd, 
1H, 4, J = 2.6, J = 2.9), 6.85 (d, 2H, 8, 12, J = 8.9), 6.65 (d, 2H, 9, 11, J = 8.9), 5.17 
(s, 2H, 13), 3.77–3.68 (m, 1H, 2'), 1.78–1.04 (m, 10H, 3'–7') 
167.31 (5), 162.70 (1), 152.77 (2), 150.52 (3), 147.30 (7), 143.38 (10), 121.98 (8, 12), 
115.37 (9, 11), 114.26 (6), 108.92 (4), 48.38 (2'), 32.58 (3', 7'), 25.54 (5'), 25.18 (4', 6') 
3c 
2´
3´
8´
7´
6´
5´
4´
 
8.65 (t, 1H, 1', J = 6.2), 8.45 (d, 1H, 3, J = 5.6), 7.34 (d, 1H, 6, J = 2.3), 7.07 (dd, 
1H, 4, J = 2.6, J = 3.1), 6.86 (d, 2H, 8, 12, J = 8.6), 6.65 (d, 2H, 9, 11, J = 8.9), 5.15 
(s, 2H, 13), 3.12 (t, 2H, 2', J = 6.6), 1.66–0.84 (m, 11H, 3'–8') 
167.31 (5), 163.76 (1), 152.78 (2), 150.54 (3), 147.32 (7), 143.37 (10), 122.00 (8, 12), 
115.36 (9, 11), 114.19 (6), 108.90 (4), 45.39 (2'), 37.91 (3'), 30.86 (4', 8'), 26.50 (6'), 
25.81 (5', 7') 
3d 
2´
3´
8´
7´
6´
5´
4´
 
9.27 (t, 1H, 1', J = 6.4), 8.47 (d, 1H, 3, J = 5.6), 7.38 (d, 1H, 6, J = 2.4), 7.31–7.21 
(m, 5H, 4'–8'), 7.08 (dd, 1H, 4, J = 2.7, J = 2.9), 6.85 (d, 2H, 8, 12, J = 8.8), 6.65 (d, 
2H, 9, 11, J = 8.8), 5.16 (s, 2H, 13), 4.46 (d, 2H, 2', J = 6.4) 
167.32 (5), 163.96 (1), 152.63 (2), 150.66 (3), 147.33 (7), 143.36 (10), 139.89 (3'), 
128.70 (4', 8'), 127.81 (5', 7'), 127.22 (6'), 122.01 (8, 12), 115.38 (9, 11), 114.35 (6), 
109.09 (4), 42.91 (2') 
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Table 1. Cont. 
Compd. R 1H and 13C-NMR spectra/δ ppm, J/Hz 
3e 
2´
3´
4´
9´
8´
7´
6´
5´
 
8.78 (t, 1H, 1', J = 6.0), 8.44 (d, 1H, 3, J = 5.5), 7.35 (d, 1H, 6, J = 2.6), 7.30–7.18 
(m, 5H, 5'–9'), 7.08 (dd, 1H, 4, J = 2.6, J = 3.1), 6.86 (d, 2H, 8, 12, J = 8.7), 6.65 (d, 
2H, 9, 11, J = 8.7), 5.17 (s, 2H, 13), 3.52 (q, 2H, 2', J = 7.0), 2.84 (t, 2H, 3', J = 7.5) 
166.80 (5), 163.23 (1), 152.14 (2), 150.09 (3), 146.84 (7), 142.83 (10), 139.29 (4'), 
128.53 (5', 9'), 128.31 (6', 8'), 126.06 (7'), 121.51 (8, 12), 114.86 (9, 11), 113.73 (6), 
108.42 (4), 39.55 (2'), 24.06 (3') 
4a 2´
6´ 5´
4´
3´
 
9.20 (s, 1H, 15), 8.98 (s, 1H, 13), 8.50 (d, 1H, 3, J = 5.4), 8.47 (d, 1H, 1', J = 6.7), 
8.17 (s, 1H, 17), 7.69–7.58 (m, 4H, 20, 21, 8, 12), 7.38 (d, 1H, 6, J = 2.6), 7.18–7.14 
(m, 3H, 4, 9, 11), 4.23–4.16 (m, 1H, 2'), 1.99–1.53 (m, 8H, 3'–6') 
166.47 (5), 163.21 (1), 152.94 (14), 152.92 (2), 150.75 (3), 148.36 (7), 139.80 (10), 
137.52 (16), 132.44 (22), 124.00 (19), 123.58 (20), 122.54 (18), 121.86 (8, 12), 
120.99 (9, 11), 117.36 (17), 117.28 (21), 114.59 (6), 109.20 (4), 51.07 (2'), 32.55 (3', 6'), 
23.96 (4', 5') 
4b 
2´
7´
6´
5´
4´
3´
 
9.45 (s, 1H, 15), 9.19 (s, 1H, 13), 8.50 (d, 1H, 3, J = 5.6), 8.40 (d, 1H, 1', J = 8.6), 
8.11 (s, 1H, 17), 7.68–7.58 (m, 4H, 20, 21, 8, 12), 7.39 (d, 1H, 6, J = 2.4), 7.18–7.14 
(m, 3H, 4, 9, 11), 3.75–3.72 (m, 1H, 2'), 1.78–1.56 (m, 10H, 3'–7') 
166.49 (5), 162.61 (1), 152.99 (14), 152.93 (2), 150.77 (3), 148.31 (7), 139.85 (10), 
137.56 (16), 132.47 (22), 123.93 (19), 123.45 (20), 122.46 (18), 121.87 (8, 12), 
120.84 (9, 11), 117.21 (17), 117.13 (21), 114.59 (6), 109.31 (4), 48.42 (2'), 32.57 (3', 7'), 
25.53 (5'), 25.18 (4',6') 
4c 
2´
3´
8´
7´
6´
5´
4´
 
9.20 (s, 1H, 15), 8.97 (s, 1H, 13), 8.69 (t, 1H, 1', J = 6.1), 8.51 (d, 1H, 3, J = 5.5), 
8.12 (s, 1H, 17), 7.69–7.58 (m, 4H, 20, 21, 8, 12), 7.38 (d, 1H, 6, J = 2.5), 7.18–7.14 
(m, 3H, 4, 9, 11), 3.13 (t, 2H, 2', J = 6.4), 1.66–0.78 (m, 11H, 3'–8') 
166.49 (5), 163.66 (1), 152.94 (14), 152.92 (2), 150.78 (3), 148.35 (7), 139.80 (10), 
137.52 (16), 132.45 (22), 124.04 (19), 123.58 (20), 122.58 (18), 121.90 (8, 12), 
120.99 (9, 11), 117.36 (17), 117.29 (21), 114.57 (6), 109.22 (4), 45.41 (2'), 37.90 
(3'), 30.86 (4', 8'), 26.50 (6'), 25.81 (5', 7') 
4d 
2´
3´
8´
7´
6´
5´
4´
 
9.49 (s, 1H, 15), 9.31 (t, 1H, 1', J = 6.3), 9.22 (s, 1H, 13), 8.54 (d, 1H, 3, J = 5.6), 
8.12 (s, 1H, 17), 7.65–7.58 (m, 4H, 20, 21, 8, 12), 7.42 (d, 1H, 6, J = 2.4), 7.31–7.16 
(m, 8H, 4, 9, 11, 4'–8'), 4.46 (d, 2H, 2', J = 6.3) 
166.50 (5), 163.85 (1), 153.00 (14), 152.80 (2), 150.91 (3), 148.27 (7), 139.86 (10), 
137.60 (16), 132.48 (22), 128.70 (4', 8'), 127.83 (5', 7'), 127.23 (6'), 126.66 (3'), 
123.99 (19), 123.43 (20), 122.57 (18), 121.91 (8, 12), 120.83 (9, 11), 117.18 (17), 
117.11 (21), 114.67 (6), 109.45 (4), 42.92 (2') 
4e 
2´
3´
4´
9´
8´
7´
6´
5´
 
9.20 (s, 1H, 15), 8.98 (s, 1H, 13), 8.81 (t, 1H, 1', J = 5.8), 8.50 (d, 1H, 3, J = 5.6), 
8.12 (s, 1H, 17), 7.68–7.58 (m, 4H, 20, 21, 8, 12), 7.39 (d, 1H, 6, J = 2.3), 7.31–7.14 
(m, 8H, 4, 9, 11, 4'–8'), 3.51 (q, 2H, 2', J = 6.9), 2.84 (t, 2H, 3', J = 7.4) 
166.48 (5), 163.62 (1), 152.94 (14), 152.81 (2), 150.83 (3), 148.33 (7), 139.79 (10), 
137.53 (16), 132.46 (22), 129.03 (5', 9'), 128.81 (6', 8'), 126.73 (4'), 126.57 (7'), 
125.11 (19), 123.60 (20), 122.58 (18), 121.90 (8, 12), 121.01 (9, 11), 117.60 (17, 21), 
114.60 (6), 109.24 (4), 40.83 (2'), 35.50 (3') 
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2.2. Biological Evaluation 
2.2.1. Cytostatic Activity 
The experiments were carried out on six human tumour and one murine cell lines, which are 
derived from five solid tumour types and two (one murine and one human) suspension tumour cell 
lines. The following cell lines were used: HCT 116 (colon carcinoma), SW 620 (colon carcinoma), 
MCF-7 (breast carcinoma), H 460 (lung carcinoma), L1210 (murine leukemia), CEM (human 
lymphoma) and HeLa (cervix carcinoma). The results of the cytostatic effect of the tested compounds are 
presented in Table 2. Compounds 2a–e and 3a–c showed no, or rather modest antiproliferative effect, 
only at the maximal tested concentration (104 M). Compounds 3d and 3e with a benzene ring in the 
amide moiety, exerted a somewhat stronger (but still rather poor) cytostatic effect (IC50 ≈ 2090 µM).  
In contrast, compounds 4a–e showed the most prominent effect with IC50 values in the lower 
micromolar range (IC50 from 1 to 4.3 M, with an average of 2.6 ± 1.6), but without substantial 
selectivity between the tumour cell lines. The compounds were also equally cytostatic against primary 
human embryonic lung (HEL) fibroblast cells (Table 2). The obtained data clearly point to the 
obligatory presence of the [4-chloro-3-(trifluoromethyl)phenyl]carbamoyl group being crucial for high 
potency. Also, the 4a–e series of compounds are far more lipophilic than the 2 and 3 series of 
compounds, which may be related to their increased cytostatic potential. The cytostatic activities of 
compounds 4a–e are comparable with the data obtained for sorafenib 10 or even better (median IC50 
value for sorafenib is 4.3 M; twenty of 23 cell lines had values between 1.0 and 10.0 M), which 
indicate that the pyridine-2-carboxamide modifications had a minor effect on the antiproliferative activity. 
Log P of sorafenib is 3.76, while amides 4a–e have log P values between 4.89 and 5.77 (Table 2) 11. 
Table 2. IC50 values of compounds 2a–e, 3a–e, and 4a–e a. 
Compd. 
log P 
(Clog P) b 
Tumour cell growth/IC50 (µmol·L−1)  
HCT 116 SW 620 MCF-7 H 460 L1210 CEM HeLa HEL 
2a 
1.95 
(2.72) 
>100 >100 >100 ≥100 >100 >100 >100 >100 
2b 
2.37 
(3.28) 
>100 >100 ≥100 35 ± 12 >100 >100 >100 >100 
2c 
2.80 
(3.90) 
≥100 ≥100 ≥100 >100 >100 >100 >100 >100 
2d 
2.55 
(3.22) 
≥100 71 ± 28 ≥100 >100 ≥100 ≥100 >100 >100 
2e 
2.83 
(3.35) 
≥100 >100 57 ± 46 >100 >100 >100 >100 >100 
3a 
2.13 
(2.80) 
54 ± 21 ≥100 53 ± 40 >100 121 ± 50.5 ≥100 77 ± 3.4 >100 
3b 
2.54 
(3.36) 
37 ± 1 ≥100 ≥100 65 ± 33 234 ± 4.5 >100 >100 >100 
3c 
2.97 
(3.98) 
≥100 ≥100 ≥100 >100 163 ± 147 >100 >100 >100 
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Table 2. Cont. 
Compd. 
log P 
(Clog P) b 
Tumour cell growth/IC50 (µmol·L−1) 
HCT 116 SW 620 MCF-7 H 460 L1210 CEM HeLa HEL 
3d 
2.73 
(3.30) 
29 ± 4 37 ± 6 29 ± 13 42 ± 9 66 ± 3.1 94 ± 2.2 94 ± 1.9 >100 
3e 
3.01 
(3.43) 
25 ± 2 20 ± 7 34 ± 17 20 ± 0.0 63 ± 8.9 42 ± 3.0 39 ± 3.0 >100 
4a 
4.89 
(6.93) 
3.0 ± 0.5 2.0 ± 0.4 4.0 ± 1.0 1.0 ± 0.0 4.2 ± 0.8 4.2 ± 0.6 3.1 ± 0.6 2.8 ± 0.0 
4b 
5.31 
(7.49) 
3.0 ± 0.8 3.0 ± 0.2 2.0 ± 0.6 2.0 ± 0.0 3.2 ± 1.7 3.6 ± 0.9 3.0 ± 0.2 3.2 ± 0.2 
4c 
5.73 
(8.11) 
3.0 ± 1.0 3.0 ± 0.4 2.0 ± 0.1 2.0 ± 0.2 1.8 ± 0.3 2.0 ± 0.5 2.7 ± 1.8 2.9 ± 0.0 
4d 
5.49 
(7.42) 
2.0 ± 0.8 2.0 ± 0.08 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.4 4.3 ± 0.4 2.6 ± 0.6 3.1 ± 0.2 
4e 
5.77 
(7.55) 
3.0 ± 0.7 2.0 ± 0.4 2.0 ± 0.1 2.0 ± 0.2 2.2 ± 0.2 2.5 ± 0.9 1.7 ± 0.2 4.6 ± 0.36 
Sorafenib 
3.76 
(5.46) 
3.0 ± 0.8 6.0 ± 1.0 3.0 ± 0.7 3.0 ± 0.8 4.1 ± 0.0 3.4 ± 0.5 3.7 ± 0.6 7.5 ± 0.7 
a IC50, the concentration that causes 50% growth inhibition; b Lipophilicity was theoretically calculated by the 
CLOGP Programme of Biobyte Corp. 11. 
2.2.2. Antimetabolic Activity 
A variety of compounds (2a, 3a, 4a with a cycloalkyl substituent directly attached to nitrogen atom, 
2c, 3c, 4c with a cycloalkyl bound to nitrogen through a short spacer and 2e, 3e, 4e with an aromatic 
substituent) have been investigated on their inhibitory activity against DNA, RNA and protein 
synthesis in CEM cell cultures 12. The compounds were equally inhibitory to dThd (DNA synthesis), 
Urd (RNA synthesis) and Leu (protein synthesis) incorporation into TCA-insoluble cell material.  
The 2 series of compounds were least inhibitory whereas the 4 series were most inhibitory (IC50 in the 
lower micromolar range). Their antimetabolic IC50 values closely corresponded to their antiproliferative 
IC50 values. They also behaved as sorafenib in terms of antimetabolic potential (Table 3). 
Table 3. Antimetabolic activity of tested compounds in CEM cell cultures. 
CEM IC50 (µmol·L
−1) 
[CH3-3H]dThd [5-3H]Urd [4,5-3H]Leu 
2a >100 >100 >100 
2c >100 >100 >100 
2e >100 >100 >100 
3a >100 >100 >100 
3c >100 92.1 ± 43.0 70.6 ± 27.6 
3e >100 49.9 ± 17.9 >100 
4a 12.5 ± 6.7 7.7 ± 2.1 6.1 ± 0.7 
4c 20.1 ± 10.9 12.2 ± 8.4 27.4 ± 12.7 
4e 12.7 ± 9.0 6.6 ± 1.8 11.8 ± 7.7 
Sorafenib 8.6 ± 1.1 7.1 ± 0.2 12.0 ± 7.0 
a 50% Inhibitory concentration or compound concentration required to inhibit 
tritated dThd, Urd or Leu into TCA-insoluble cell materials. 
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2.2.3. Uptake and Efflux of Tested Compounds in CaCo-2 Cell Cultures 
Derivatives 2a, 3a and 4a have been examined for their efficiency of uptake at the apical site and 
subsequent delivery at the basolateral site of colon carcinoma CaCo-2 cell cultures 13. This model 
system can be used to predict the potential of a drug to show oral bioavailability. Sorafenib was 
included as the reference compound. Whereas 2a and 3a showed a higher drug delivery at the 
basolateral site than sorafenib in function of exposure time, 4a performed less efficient than the 
reference compound (Figure 1). The molecular basis of this phenomenon is yet unclear. 
Figure 1. Release of the tested compounds at the basolateral side by CaCo-2 cell cultures. 
Hundred micromolar concentrations of the tested compounds were added at the apical side 
of confluent CaCo-2 cell cultures, and the appearance of the intact tested compound at the 
basolateral side was measured by HPLC analysis. 
 
3. Experimental Section 
3.1. Chemistry 
3.1.1. General 
Melting points were determined on a Stuart Melting Point Apparatus SMP3 and were uncorrected. 
IR spectra were recorded on a FTIR Perkin Elmer Paragon 500 spectrometer. 1H- and 13C-NMR 
spectra were recorded on a Bruker AV-600 spectrometer operating at 300.13 and 75.47 MHz for the 
1H and 13C nuclei, respectively. Samples were measured in DMSO-d6 solutions at 20 °C in 5 mm 
NMR tubes. Chemical shifts () were referred to TMS. Mass spectra were taken on a HPLC-MS/MS 
(HPLC, Agilent Technologies 1200 Series; MS, Agilent Technologies 6410 Triple Quad). CEM 
Discover microwave reactor was used for microwave reactions. Precoated Merck silica gel 60 F254 
plates (Merck, Germany) and solvent systems petrolether/ethyl acetate/methanol (3:1:0.5; 3:1:0.25  
or 3:1:0.15), cyclohexane/ethyl acetate (1:1), petrolether/ethyl acetate (1:1), ethyl acetate and 
dichloromethane/methanol (9:1 or 9.5:0.5), were used for thin-layer chromatography. Spots were 
visualized by short-wave UV light and iodine vapour. Column chromatography was performed on 
silica gel (0.063–0.200 mm), with petroleum ether/ethyl acetate/methanol (3:1:0.5, 3:1:0.25 or 
3:1:0.15) or dichloromethane/methanol (9:1). Preparative chromatography was performed on silica gel 
Molecules 2012, 17 1132 
 
 
preparative plates using dichloromethane/methanol (9:1 or 9.5:0.5) as eluents. Picolinic acid,  
4-amino-phenol and 4-chloro-3-(fluoromethyl)phenyl isocyanate were purchased from Acros Organics, 
cyclopentylamine, cyclohexylamine, cyclohexylmethylamine, benzylamine, phenylethylamine and 
potassium tert-butoxyde from Aldrich, and potassium carbonate from Kemika. Anhydrous solvents 
(DMF, CH2Cl2, toluene) were prepared prior to use. Human cell lines for cytostatic activity were 
obtained from American Type Culture Collection. 
4-Chloropyridine-2-carbonyl chloride hydrochloride (1). Compound 1 was prepared from picolinic 
acid (1.231 g, 10 mmol) and thionyl chloride (5 mL) following procedure previously described 9.  
The crude product 1 was used in the next step without further purification. 
3.1.2. General Method for the Synthesis of 4-chloropyridine-2-carboxamides 2a–e 
To a cold solution of chloride 1 (1.760 g, 10 mmol) in anhydrous toluene (10 mL) a solution of 
appropriate amine (10 mmol) and triethylamine (2.02 g, 20 mmol) in toluene (5 mL) was added 
dropwise. The reaction mixture was stirred at room temperature for 30 min and then extracted 3 times 
with saturated NaCl solution. The organic phase was dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure. The crude products 2a–e were purified by column chromatography. 
4-Chloro-N-cyclopentylpyridine-2-carboxamide (2a). From the reaction of chloride 1 (1.760 g, 10 mmol) 
and cyclopentylamine (0.086 g, 10 mmol) at room temperature for 0.5 h and column chromatography 
(mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.5 and petroleum ether/ethyl acetate 1:1) 
1.621 g (72%) of 2a was obtained; mp 7980 C; IR (KBr): max 3328, 3064, 2961, 2870, 1666, 1575, 
1556, 1519, 732 cm–1. MS/MS m/z 225.1 (M+H)+. Anal. (C11H13ClN2O) C, H, N. 
4-Chloro-N-cyclohexylpyridine-2-carboxamide (2b). From the reaction of chloride 1 (1.760 g, 10 mmol) 
and cyclohexylamine (0.099 g, 10 mmol) at room temperature for 0.5 h and column chromatography 
(mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.15) 1.243 g (52%) of 2b was obtained; mp 
116119 C; IR (KBr): max 3330, 2930, 2853, 1650, 1578, 1554, 1534, 736 cm–1. MS/MS m/z 239.1 
(M+H)+. Anal. (C12H15ClN2O) C, H, N. 
4-Chloro-N-cyclohexylmethylpyridine-2-carboxamide (2c). From the reaction of chloride 1 (1.760 g, 
10 mmol) and cyclohexylmethylamine (1.132 g, 10 mmol) at room temperature for 0.5 h and column 
chromatography (mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.15) 0.999 g (40%) of 2c 
was obtained; mp 107108 C; IR (KBr): max 3341, 3089, 2926, 2855, 1649, 1537, 736 cm–1. MS/MS 
m/z 253.1 (M+H)+. Anal. (C13H17ClN2O) C, H, N. 
4-Chloro-N-benzylpyridine-2-carboxamide (2d). From the reaction of chloride 1 (1.760 g, 10 mmol) 
and benzylamine (1.072 g, 10 mmol) at room temperature for 0.5 h and column chromatography 
(mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.25) 1.577 g (64%) of 2d was obtained; mp 
7072 C; IR (KBr): max 3326, 1649, 1578, 1552, 1536, 736, 725 cm–1. MS/MS m/z 269.1 (M+Na)+. 
Anal. (C13H11ClN2O) C, H, N. 
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4-Chloro-N-phenylethylpyridine-2-carboxamide (2e). From the reaction of chloride 1 (1.760 g, 10 mmol) 
and phenylethylamine (1.212 g, 10 mmol) at room temperature for 0.5 h and column chromatography 
(mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.15) 1.404 g (54%) of 2e was obtained; mp 
6062 C; IR (KBr): max 3346, 1657, 1556, 1531, 733, 700 cm–1. MS/MS m/z 261.1 (M+H)+. Anal. 
(C14H13ClN2O) C, H, N. 
3.1.3. General Method for the Synthesis of 4-(4-aminophenoxy)-pyridine-2-carboxamides 3a–e 
A suspension of t-BuOK (0.056 g, 0.5 mmol) and 4-aminophenol (0.054 g, 0.5 mmol) in anhydrous 
DMF (5 mL) was stirred at room temperature for 30 min. The corresponding 4-chloropicolinamide 2a–e 
(0.5 mmol) and potassium carbonate (0.034 g, 0.25 mmol) were added. The reaction mixture was 
stirred in microwave reactor for 10 min (P = 150 W, t = 173 °C). DMF was evaporated under reduced 
pressure. The residue was dissolved in ethyl acetate end extracted with saturated NaCl solution.  
The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. 
The crude products 3a–e were purified by column chromatography or by recrystallization. 
4-(4-Aminophenoxy)-N-cyclopentylpyridine-2-carboxamide (3a). From the reaction of amide 2a (0.112 g, 
0.5 mmol) and purification by column chromatography [mobile phase dichloromethane/methanol 
(9:1)] 0.069 g (46%) of 3a was obtained; viscous oil; IR (KBr): max 3353, 2958, 2870, 1666, 1608, 
1590, 1521, 1502, 1470, 1284, 1198, 836 cm–1. MS/MS m/z 298.2 (M+H)+. Anal. (C17H19N3O2) C, H, N. 
4-(4-Aminophenoxy)-N-cyclohexylpyridine-2-carboxamide (3b). From the reaction of amide 2b (0.119 g, 
0.5 mmol) and recrystallization from methanol/water 0.075 g (48%) of 3b was obtained; mp 150153 C. 
IR (KBr): max 3357, 3316, 2928, 2855, 1660, 1566, 1523, 1506, 839 cm–1. MS/MS m/z 312.2 (M+H)+. 
Anal. (C18H21N3O2) C, H, N. 
4-(4-Aminophenoxy)-N-cyclohexylmethylpyridine-2-carboxamide (3c). From the reaction of amide 2c 
(0.126 g, 0.5 mmol) and purification by column chromatography (mobile phase petroleum ether/ethyl 
acetate/methanol 3:1:0.15) 0.075 g (46%) of 3c was obtained; mp 135137 C; IR (KBr): max 3390, 
3364, 3194, 2924, 2838, 1680, 1526, 1504, 1299, 1195, 844 cm–1. MS/MS m/z 326.2 (M+H)+. Anal. 
(C19H23N3O2) C, H, N. 
4-(4-Aminophenoxy)-N-benzylpyridine-2-carboxamide (3d). From the reaction of amide 2d (0.123 g, 
0.5 mmol) and purification by column chromatography (mobile phase petroleum ether/ethyl 
acetate/methanol 3:1:0.5) 0.121 g (76%) of 3d was obtained; viscous oil; IR (KBr): max 3348, 3062, 
2925, 1665, 1590, 1566, 1526, 1501, 1468, 1261, 1197, 834, 699 cm–1. Anal. (C19H17N3O2) C, H, N. 
4-(4-Aminophenoxy)-N-phenylethylpyridine-2-carboxamide (3e). From the reaction of amide 2e (0.130 g, 
0.5 mmol) and purification by column chromatography (mobile phase petroleum ether/ethyl 
acetate/methanol 3:1:0.5) 0.115 g (69%) of 3e was obtained; viscous oil; IR (KBr): max 3354, 3229, 
3061, 3027, 2928, 2862, 1665, 1607, 1590, 1526, 1504, 1469, 1285, 1198, 838, 670 cm–1. MS/MS m/z 
334.2 (M+H)+. Anal. (C20H19N3O2) C, H, N. 
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3.1.4. General Procedure for the Synthesis of 4-4-4-Chloro-3-(trifluoromethyl)phenylcarbamoyl-
aminophenoxy-pyridine-2-carboxamides 4a–e 
A solution of 4-(4-aminophenoxy)-picolinamide 3a–e (0.1 mmol) and 4-chloro-3-(fluoromethyl)-
phenyl isocyanate (0.12 mmol) in anhydrous dichloromethane (3 mL) was stirred for 16 h at room 
temperature under nitrogen atmosphere. Solvent was evaporated under reduced pressure and the 
residue was dissolved in ethyl acetate and extracted three times with brine. The organic phase was 
dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude products  
4a–e were purified by column chromatography, preparative chromatography or by recrystallization. 
4-4-4-Chloro-3-(trifluoromethyl)phenylcarbamoylaminophenoxy-N-cyclopentyl-pyridine-
2-carboxamide (4a). From the reaction of compound 3a (0.030 g, 0.1 mmol) and purification by 
column chromatography (mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.5) 0.051 g (98%) 
of 4a was obtained; viscous oil; IR (KBr): max 3353, 2962, 2872, 1718, 1654, 1595, 1546, 1506, 1420, 
1306, 1199, 1176, 1140, 838, 663 cm–1. MS/MS m/z 519.1 (M+H)+. Anal. (C25H22ClF3N4O3) C, H, N. 
4-4-4-Chloro-3-(trifluoromethyl)phenylcarbamoylaminophenoxy-N-cyclohexyl-pyridine-
2-carboxamide (4b). From the reaction of compound 3b (0.031 g, 0.1 mmol) and purification by 
column chromatography (mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.5) and 
preparative chromatography (mobile phase dichloromethane/methanol 9:1) 0.023 g (43%) of 4b was 
obtained; mp 110114 C; IR (KBr): max 3348, 3072, 2932, 2855, 1716, 1650, 1596, 1548, 1505, 
1484, 1419, 1293, 1197, 1175, 1137, 840, 663 cm–1. MS/MS m/z 533.2 (M+H)+. Anal. 
(C26H24ClF3N4O3) C, H, N. 
4-4-4-Chloro-3-(trifluoromethyl)phenylcarbamoylaminophenoxy-N-cyclohexylmethyl-pyridine-2-
carboxamide (4c). From the reaction of compound 3c (0.033 g, 0.1 mmol) and purification by column 
chromatography (mobile phase petroleum ether/ethyl acetate 1:1) and recrystallization from 
methanol/water 0.030 g (55%) of 4c was obtained. mp 156160 C; IR (KBr): max 3353, 2962, 2872, 
1718, 1654, 1595, 1546, 1506, 1420, 1306, 1199, 1176, 1140, 838, 663 cm–1. MS/MS m/z 547.2 
(M+H)+. Anal. (C27H26ClF3N4O3) C, H, N. 
4-4-4-Chloro-3-(trifluoromethyl)phenylcarbamoylaminophenoxy-N-benzyl-pyridine-2-
carbox-amide (4d). From the reaction of compound 3d (0.032 g, 0.1 mmol) and recrystallization from 
methanol/water 0.020 g (37%) of 4d was obtained. mp 160163 C; IR (KBr): max 3351, 3132, 2926, 
2854, 1718, 1654, 1595, 1543, 1506, 1420, 1303, 1199, 1176, 1140, 837, 668 cm–1. MS/MS m/z 541.9 
(M+H)+. Anal. (C27H20ClF3N4O3) C, H, N. 
4-4-4-Chloro-3-(trifluoromethyl)phenylcarbamoylaminophenoxy-N-phenylethyl-pyridine-
2-carboxamide (4e). From the reaction of compound 3e (0.033 g, 0.1 mmol) and purification by 
column chromatography (mobile phase petroleum ether/ethyl acetate/methanol 3:1:0.15) 0.041 g 
(74%) of 4e was obtained. viscous oil; IR (KBr): max 3345, 3066, 2928, 1716, 1654, 1596, 1545, 
1505, 1483, 1419, 1299, 1198, 1175, 1134, 840, 699 cm–1. Anal. (C28H22ClF3N4O3) C, H, N. 
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3.2. Biological Evaluation 
3.2.1. Cytostatic Activity 
HCT 116, SW 620, MCF-7, and H 460 cells were cultured as monolayers and maintained in 
Dulbecco’s modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum (FBS),  
2 mmol·L–1 L-glutamine, 100 U·mL–1 penicillin and 100 μg·mL–1 streptomycin in a humidified 
atmosphere with 5% CO2 at 37 C. The growth inhibition activity was assessed as described 
previously, according to the slightly modified procedure of the National Cancer Institute, 
Developmental Therapeutics Program 14,15. Briefly, the cells were seeded onto standard 96-well 
microtiter plates on day 0. The cell concentrations were adjusted according to the cell population 
doubling time (PDT): 3000 cells/well for HCT116 and SW 620 cell lines (PDT = 20–24 h) and 4,000 
cells/well for MCF-7 cell lines (PDT = 33 h). Tested agents were then added in five consecutive 10-fold 
dilutions (10–8 to 10–4 mol·L–1) and incubated for further 72 h. Working dilutions were freshly 
prepared on the day of testing. The solvent (DMSO) was also tested for eventual inhibitory activity by 
adjusting its concentration to be the same as in working concentrations (maximal concentration of 
DMSO was 0.25%). After 72 h of incubation, the cell growth rate was evaluated by performing the 
MTT assay (Promega) which detects dehydrogenase activity in viable cells 16. The absorbency (OD, 
optical density) was measured on a microplate reader at 570 nm. Each test point was performed in 
quadruplicate in at least three individual experiments. The results are expressed as IC50, which is the 
concentration necessary for 50% of inhibition. The IC50 values for each compound are calculated from 
dose-response curves using linear regression analysis, using FORCAST function in Excel, by fitting 
the test concentrations that give PG (percentage of growth) values above and below the reference value 
(i.e., 50%). Each result is a mean value from three separate experiments. 
The cytostatic activity of the tested compounds against murine leukemia L1210, human cervix 
carcinoma HeLa, human embrionic lung (HEL) and T-lymphocyte CEM cells was determined with 
cells grown in suspension (L1210, CEM) or monolayers (HeLa, HEL) in 200 µL-wells of 96-well 
microtiter plates (initial cell number: 5–7.5 × 104 cells/well). After 48 (L1210) or 72 (CEM, HeLa, HEL) h, 
the tumour cell number was determined by the use of a Coulter counter. 
3.2.2. Antimetabolic Activity and Drug Influx/Efflux Assay in CaCo-2 Cell Cultures 
The procedures have been modified from previously described methods 12,13. Human CEM cells 
were seeded in 96-well microtiter plates at 10 × 104 cells/200 µL-well in the presence of serial 
dilutions of the tested compounds. Then, 0.25 µCi of [CH3-3H]dThd (radiospecificity: 52 Ci/mmol) or 
1 µCi of [5-3H]Urd (radiospecificity: 26 Ci/mmol) or [4,5-3H]Leu (radiospecificity: 160 Ci/mmol) 
were added and the drug-exposed tumour cell cultures further incubated at 37 °C for ~20 h. Then the 
content of each well was transfered to glass fiber discs (Wattman, GE Healthcare, Maidstone, UK), 
mounted on a manifold (Millipore, Billerica, MA, USA) and subsequently washed with PBS  
(to remove the radiolabel material that has not been incorporated in the cellular macromolecules),  
10% and 5% trichoroacetic acid (TCA) (to precipitate DNA, RNA and proteins) and ethanol.  
Then, the radioactivity (TCA precipitate) associated with each disc was determined in a liquid 
scintillation counter (Packard, Palo Alto, CA, USA). 
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Human colon carcinoma CaCo-2 cells were seeded in the inner wells of a double-chamber-well-tray 
at 150,000 cells (0.5 mL) per 1 mL-well. The outer wells also contain 0.5 mL medium (without cells). 
After the cells were grown to confluency (~2 days) at 37 °C in a humidified CO2-controlled 
atmosphere, 100 µmol·L–1 tested compound (final concentration) was added to the inner well, and the 
medium from the outer wells was replaced by 800 µL PBS (containing 10% foetal bovine serum).  
At different time points (i.e., 0, 2, 4, 6, 8 and 24 h), 50 µL was removed from the outer wells and 
mixed with 100 µL cold methanol. The mixture was left on ice for 10 min, centrifuged to remove the 
precipitate, and the supernatant was analysed by HPLC (reversed phase) to determine the drug 
concentration that appeared in the outer wells (reflecting basolateral drug efflux) in function of time. 
4. Conclusions 
The synthetic pathway leading to five new sorafenib amide derivatives is described. The final 
compounds, as well as intermediates, are fully chemically characterized. Their cytostatic activity was 
tested on a panel of seven tumour cell lines, on which they exerted pronounced, but nonselective 
antiproliferative activity at the lower micromolar range, comparable to the activity of sorafenib itself. 
Detailed pharmacological and pharmacokinetic evaluation still remain to be done to compare the 
sorafenib derivatives described herein with the parent compound. 
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